435 Studies Now Enrolling
A Phase 1b Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax as Single Agent and in Combination with Azacitidine in Subjects with Higher-Risk Myelodysplastic Syndromes after Hypomethylating Agent Failure
A study for patients with myelodysplastic syndrome (MDS) using study drug venetoclax
| Sponsor: | AbbVie |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR1076 |
| U.S. Govt. ID: | NCT02966782 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to evaluate the safety, pharmacokinetics (how much of the study drugs is present in your body at different times), and efficacy (how well the study treatment works) of venetoclax alone and of venetoclax in combination with azacitidine in subjects with higher-risk MDS after HMA-failure.
This study is closed
